* Abcellera Biologics Inc ABCL.OQ ABCL.O is expected
to show a
fall in quarterly revenue when it reports results
* The Vancouver British Columbia-based company is expected
to
report a 88.3% decrease in revenue to $11.905 million from
$101.38 million a year ago, according to the mean estimate from
8 analysts, based on LSEG data.
* Refinitiv's mean analyst estimate for Abcellera Biologics
Inc
is for a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $24.5, above its last closing price of $4.11.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 -0.11 -0.13 -0.11 Beat 15.4
Mar. 31 2023 -0.12 -0.14 -0.14 Met -3.2
Dec. 31 2022 0.00 -0.01 -0.10 Missed -1,804
.8
Sep. 30 2022 0.05 0.05 0.08 Beat 76.1
Jun. -0.01 -0.02 -0.02 Met -28.5
30 2022
Mar. 31 2022 0.40 0.38 0.54 Beat 40.6
Dec. 31 2021 0.18 0.19 0.19 Met 0.6
Sep. 30 2021 -0.07 -0.05 -0.08 Missed -52.4
This summary was machine generated November 1 at 02:40 GMT. All
figures in US dollars unless otherwise stated